Myeloid derived cells play an important role in inflammatory conditions.
Ulcerative colitis (UC) and Crohn’s disease (CD) are collectively referred to inflammatory bowel disease (IBD) due to the chronic inflammation in the lining of gastrointestinal tract. The loss of tolerance to the intestinal commensal microbiota and impaired immune response contribute to the pathogen...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Final Year Project |
Language: | English |
Published: |
2013
|
Subjects: | |
Online Access: | http://hdl.handle.net/10356/53824 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Summary: | Ulcerative colitis (UC) and Crohn’s disease (CD) are collectively referred to inflammatory bowel disease (IBD) due to the chronic inflammation in the lining of gastrointestinal tract. The loss of tolerance to the intestinal commensal microbiota and impaired immune response contribute to the pathogenesis of IBD. The regulatory T cells lose its tolerance to the enteric commensal microbiota that resulted in autoimmunity. The pathogen recognition receptors (PRRs) expressed on the epithelial cells and leucocytes recognize the pathogenic components and trigger immune response. Both events lead to the activation of innate immunity and enhanced inflammatory infiltration of immune cells to the inflamed intestine. The chronic inflammation is also involved in the neoplastic transformation and the risk of developing colorectal carcinoma (CRC) is increased. Three myeloid derived stem cell markers Cal B, CD15 and S100 are used to examine the role of these innate immune cells in concordance with the grade of severity in patients with IBD. CD15 marker has shown a good correlation between the inflammatory infiltrations, intensity of inflammatory cells and marker positivity with respect to the disease severity. This study shows that CD15 may be a potential severity marker for IBD and appropriate treatments can be taken. |
---|